A New Possibility to Treat Adolescent Depression

Medication isn’t the only route to relief. If your adolescent is experiencing depression, NeuroStar TMS is a safe and effective in-office treatment as an add-on therapy. NeuroStar uses magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. ​ ​ In a clinical study of 1,169 adolescent patients: ​ 78% cited improvement in their depression symptoms*​ 48% showed symptom relief (remission)*​ We’re here to help! Call our practice today to learn more about adding NeuroStar TMS to your loved one’s current treatment plan.​ Visit neurostar.com for full safety and prescribing information.​ ​ *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment.​ #NeuroStarProvider ​ #NeuroStarConnects​ #NeuroStar​ #NeuroStarSocial

Medication isn’t the only route to relief. If your adolescent is experiencing depression, NeuroStar TMS is a safe and effective in-office treatment as an add-on therapy. NeuroStar uses magnetic pulses to stimulate mood-regulating areas in the brain for those with depression for ages 15 and older. ​ ​ In a clinical study of 1,169 adolescent patients: ​ 78% cited improvement in their depression symptoms*​ 48% showed symptom relief (remission)*​ We’re here to help! Call our practice today to learn more about adding NeuroStar TMS to your loved one’s current treatment plan.​ Visit neurostar.com for full safety and prescribing information.​ ​ *FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment.​ #NeuroStarProvider ​ #NeuroStarConnects​ #NeuroStar​ #NeuroStarSocial